Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trial Disclosure Legislation Likely To Await PhRMA, AMA Discussions

Executive Summary

The next step in the push to create a national database of clinical trial results is likely to be discussion among stakeholders rather than legislation

You may also be interested in...



Rx Price Reports To Medicare, Medicaid On IG Study List For 2005

The HHS Inspector General will conduct several reviews of drug manufacturers' price reporting for Medicare and Medicaid, IG's fiscal 2005 work plan says

Rx Price Reports To Medicare, Medicaid On IG Study List For 2005

The HHS Inspector General will conduct several reviews of drug manufacturers' price reporting for Medicare and Medicaid, IG's fiscal 2005 work plan says

Clinical Trial Registries Will Be Mandatory, Sen. Clinton Predicts

Congress will act to make clinical trial registries mandatory, Sen. Hillary Rodham Clinton (D-N.Y.) predicted during the Bear Stearns conference in New York Sept. 13

Related Content

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel